


PHARMACEUTICAL 2020



Homology Medicines Inc. Rank 125 of 362





PHARMACEUTICAL 2020



Homology Medicines Inc. Rank 125 of 362

The relative strengths and weaknesses of Homology Medicines Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Homology Medicines Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 182% points. The greatest weakness of Homology Medicines Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 85% points.

The company's Economic Capital Ratio, given in the ranking table, is -76%, being 227% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	266,577
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,374
Liabilities, Non-Current	30,142
Other Assets	1,274
Other Compr. Net Income	260
Other Expenses	0
Other Liabilities	9,544
Other Net Income	6,027
Property and Equipment	42,716
Research and Development	89,398
Revenues	1,666
Selling, General and Administrative Expense	22,211

Output Variable	Value in 1000 USD
Assets	310,567
Liabilities	52,060
Expenses	111,609
Stockholders Equity	258,507
Net Income	-103,916
Comprehensive Net Income	-103,786
Economic Capital Ratio	-76%